Clik here to view.
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global...
View ArticleClik here to view.
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
CANbridge CAN106 Phase 1 Data Presented at the European Hematology...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228) , a China and US-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival...
TOKYO & BASKING RIDGE, N.J. Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s (TSE:5468) quizartinib combined with standard induction and consolidation...
View ArticleClik here to view.
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
PALO ALTO, Calif. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and...
View ArticleClik here to view.
Organon Enters into Global License Agreement to Commercialize Henlius’...
JERSEY CITY, N.J. Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai...
View ArticleClik here to view.
Children’s Hospital Los Angeles: The Best Care for Kids in California and the...
LOS ANGELES Children’s Hospital Los Angeles (CHLA) continues its streak of being California’s top hospital for pediatric care and specialty services, according to U.S. News & World Report’s...
View ArticleClik here to view.
Children’s Hospital Los Angeles：美国加州和太平洋地区最好的儿童护理机构
洛杉矶 (美国商业资讯)–根据今天发布的《美国新闻与世界报道》的“2022-23 年度最佳儿童医院”榜单，Children’s Hospital Los Angeles (CHLA) 蝉联“加州最佳儿科护理和专科服务医院”美誉。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20220613005851/zh-CN/...
View ArticleClik here to view.
Dr. Reddy’s Laboratories announces the launch of the generic version of...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today...
View ArticleClik here to view.
Exscientia报告健康志愿者1a期研究的顶线数据，表明EXS-21546可靶向抑制A2A受体信号传导
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天发布其EXS-21546 1期健康志愿者研究数据。EXS-21546是由Exscientia和Evotec SE（法兰克福证券交易所：EVT,...
View ArticleClik here to view.
Guardant Health完成了对Guardant Health AMEA合资公司的收购
加州帕洛阿托 (美国商业资讯)–领先的精准肿瘤医学公司Guardant Health, Inc. (NASDAQ:GH)今天宣布，其已收购软银及其附属公司持有的Guardant Health AMEA, Inc.的剩余股份，从而使公司获得了对整个亚洲、中东和非洲(AMEA)地区业务的全面掌控。 据估计，世界上超过一半的新发癌症病例来自亚洲、中东和非洲(AMEA)。1此次收购将让Guardant...
View ArticleClik here to view.
ガーダントヘルスが合弁会社Guardant Health AMEAの買収を完了
米カリフォルニア州パロアルト （ビジネスワイヤ） — がん精密医療の大手企業であるガーダントヘルス（NASDAQ:GH）は本日、ソフトバンクとその関連会社が保有するGuardant Health AMEA, Inc.の残りの株式を購入し、アジア・中東・アフリカ地域全体の事業を完全に掌握したと発表しました。...
View ArticleClik here to view.
HKSTP and Boehringer Ingelheim Venture Fund Launch Co-Incubation Programme to...
HONG KONG & INGELHEIM, Germany Hong Kong Science and Technology Parks Corporation (HKSTP) is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited...
View ArticleClik here to view.
エクセンシア、健康なボランティアで選択的A2A受容体シグナル伝達阻害を示すEXS-21546の第1a相試験のトップラインデータを発表
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は本日、健康なボランティアでEXS-21546を検討する当社第1相試験から得たデータを発表しました。EXS-21546は、エクセンシアとイボテック（Frankfurt Stock Exchange: EVT、MDAX/TecDAX、ISIN: DE0005664809、Nasdaq:...
View ArticleClik here to view.
ソレイジア・ファーマ株式会社: ダルビアス®点滴静注用135mg（一般名：ダリナパルシン、開発コード：SP-02）の製造販売承認取得（日本）に関するお知らせ
東京 （ビジネスワイヤ） — 本日、当社が2021年6月に厚生労働省へ製造販売承認申請した有機ヒ素製剤「ダルビアス®点滴静注用135mg」［一般名：ダリナパルシン、開発コード：SP-02］（以下、ダルビアス）について、「再発又は難治性の末梢性T細胞リンパ腫（Peripheral T-Cell...
View ArticleClik here to view.
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN...
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS®...
View ArticleClik here to view.
B dot Medical: Successful Irradiation With High-speed Scanning for an...
TOKYO B dot Medical Inc. has succeeded in high-speed scanning irradiation for an ultra-compact proton therapy system under development. That confirmed that the system under development is capable of...
View ArticleClik here to view.
苏爱康医药：日本核准DARVIAS®针剂135毫克（通用名：DARINAPARSIN/开发代码：SP-02）
东京 (美国商业资讯)–苏爱康医药（Solasia Pharma K.K.，TSE: 4597，总部：日本东京，总裁兼首席执行官：Yoshihiro...
View Article